Skip to main content
OpenTrials
Completed

NCT Number: NCT02447393

Phase 1 Study of Levocetirizine

This is a single center, single blind, single dose, randomized, partial cross-over study to confirm bioequivalence between levocetirizine and cetirizine.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–64 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

GSK Investigational Site

Kagoshima, 890-0081, Japan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Japanese healthy male subjects aged between 20 and 64 years of age inclusive. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, laboratory studies, and other tests.
  • Body weight ≥ 50 kg and BMI within the range 18.50-25.00 kg/m2 inclusive.
  • Non-smokers (at least 6 months).
  • Clinical laboratory tests data obtained at screening meet the following:

AST(GOT), ALT(GPT), total-bilirubin, BUN, creatinine, uric acid,: below the upper normal range

  • Normal 12-lead EGC finding at screening; QTc interval <450msec
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion criteria

  • The subject has any clinically relevant abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator.
  • The subject has an allergy for any drug or idiosyncrasy.
  • The subject has a history of allergic rhinitis.
  • The subject has a history or presence of clinically significant gastrointestinal, hepatic or renal disease or other condition known to interfere with absorption, distribution, metabolism or elimination of drugs.
  • The subject is currently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
  • The subject has participated in a clinical study with an investigational or a non-investigational drug or device during the previous 4 months.
  • The subject has a history or current conditions of drug abuse or alcoholism.
  • History of regular alcohol consumption exceeding on average, 14 drinks/week (1 drink = 150mL of wine or 360mL of beer or 45mL of 80 proof distilled spirits).
  • The subject is positive for urine drug screening.
  • The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody.
  • The subject has donated a unit of blood ">400mL" within the previous 4 months or ">200mL" within the previous 1 month.

Treatment and study plan

Levocetirizine

Drug

levocetirizine

Cetirizine

Drug

cetiridine

Placebo

Drug

placebo

Primary outcomes

  1. AUC0-48 of levocetirizine

    Time frame: predose,0.25,0.5,1,1.5,2,3,4,6,9,12,16,24,36, 48 hours post-dose

    Area Under the time-concentlation curve

  2. Cmax of levocetirizine

    Time frame: predose,0.25,0.5,1,1.5,2,3,4,6,9,12,16,24,36, 48 hours post-dose

    maximum concentration

Secondary outcomes

  1. Number of Adverse events

    Time frame: predose,1,24 48 hours post-dose

  2. Changes in clinical laboratory tests

    Time frame: predose,24,48 hours post-dose

  3. Changes in vital signs

    Time frame: predose,1,24,48 hours post-dose

  4. Changes in 12-lead ECG.

    Time frame: predose,1,24,48 hours post-dose

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Single Blind, Randomized, Single Oral Dose Study to Compare the Oral Disposition of Levocetirizine When Given Alone (5mg) or as the Racemate (Cetirizine 10mg), and to Investigate the Safety and Tolerability and the Pharmacokinetics of Levocetirizine and Cetirizine, Following a Single Dose in Healthy Japanese Male Subjects

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
May 18, 2015
Registry last updated
Aug 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.